JERSEY CITY, N.J., May 2, 2011 /PRNewswire/ — Aoxing
Pharmaceutical (NYSE Amex:
AXN) (“Aoxing Pharma”), a specialty pharmaceutical company
focusing on research, development, manufacturing and distribution
of narcotic and pain-management products, announced that its
operating subsidiary in China, Hebei Aoxing Pharmaceutical Group
Company, has been granted a patent by the State Intellectual
Property Office of The People’s Republic of China for naloxone
sublingual film. The Chinese patent, ZL2005.1.0125279.7,
covers a unique sublingual film formulation of naloxone that can be
dissolved rapidly under the tongue.
Naloxone is an opioid receptor antagonist that is used
clinically to relieve life-threatening depression of the central
nervous system and respiratory system, caused by overdose of
morphine and other opioids. It may also be used as an
adjunctive therapy to increase blood pressure in the treatment of
septic shocks. It is most commonly injected intravenously for
fastest action. Oral delivery is used in emergent care due to
slow and poor absorption. However, injection is inconvenient
and requires a nurse to administer it. The sublingual film
developed by Aoxing Pharma can be dissolved in under 30 seconds and
allows the drug to diffuse into the blood through tissues under the
tongue. The rapid and more efficient absorption of the
formulation makes it a convenient alternative to injection.
Mr. Zhenjiang Yue, Chairman and CEO of Aoxing Pharma, commented,
“I would like to thank our research and development team for its
dedication in driving forward this unique product, now proprietary
to Aoxing. The convenient administration of naloxone could
win critical time in emergency and save lives. We look forward to
developing this new therapeutic delivery method for this important
market.”
About Aoxing P
‘/>”/>
SOURCE
